Key Points
• Novel FVIII variant (FVIII-RH) with enhanced stability and procoagulant activity in both in vitro and in vivo models.
• FVIII-RH is efficacious and safe, thus it is an attractive molecule for protein replacement and as a transgene in gene therapy strategies
Introduction
Hemophilia is an X-linked bleeding disease caused by deficiency in coagulation factor VIII (FVIII) or factor IX (FIX). Hemophilia A (HA) affects 1:5000 males born worldwide and represents 80% of the cases of hemophilia. Current management of hemophilia is based on protein replacement, but due to its high cost, only ~20% of patients receive regular treatment. Gene replacement, gene repair, or genome editing are promising strategies for the curative treatment of hemophilia 1 . Recent success on the use of adeno-associated viral (AAV) vectors for liver expression of clotting factor IX (hemophilia B) raises the possibility that a similar approach for HA could be envisioned 2 .
Preclinical studies in mouse models followed by canine models of severe HA using liver-directed AAV vectors showed that the therapeutic dose likely will be higher than those determined for hemophilia B [3] [4] [5] . Thus, there is a fundamental interest in optimizing the expression of the transgene that could reduce the therapeutic vector dose. 6, 7 . Recombinant FVIII-BDD has been efficacious and safe in the clinical management of HA patients over the last several decades 8 . Recently, we generated a canine version of the BDD-FVIII protein 9 . We uncovered that in comparison with human FVIII, the canine protein exhibits enhanced biological activity.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Canine BDD-FVIII protein was secreted predominantly in a single-chain form, whereas the human BDD-FVIII is predominantly secreted as a heterodimer form. The activated form of canine FVIII was more stable than activated human FVIII 9 . The underlying mechanisms for these differences are not known. We hypothesized that canine BDD-FVIII remained as a single chain protein due to differences in the amino acid recognition sequence for the intracellular protease-paired basic amino acid cleaving enzyme (PACE)/furin. The consensus cleavage sequence is characterized by arginine-x-xarginine (RxxR), and alignments of several mammals showed that canine FVIII had a unique sequence with histidine (HxxR), whereas RxxR was the common sequence in other species, including human, porcine, and murine FVIII [10] [11] [12] [13] . Here we demonstrate that in a series of biochemical studies and in vivo mouse models of HA that a single amino acid change at position R1645 to H (FVIII-RH) of human FVIII-BDD generated an enhanced functional FVIII variant without any modification in the immunogenicity, as compared to the human FVIII-BDD.
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Methods

Production of recombinant FVIII-BDD forms
Human FVIII-BDD cDNA was used as a template for the generation of FVIII-RH utilizing a QuickChange™ II-XL site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA). Recombinant proteins were produced in baby hamster kidney (BHK) cells and purified as previously described 9 . Final concentrations of FVIII protein forms were determined by absorbance at 280 nm using an extinction coefficient (E 280 , 1%) of 1.60 and molecular weight of 160,000. Protein purity was assessed by loading 3 μg of FVIII protein on a reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by staining with Coomassie blue. FVIII proteins, processed by thrombin (10 nM) for 30 minutes, were run on SDS-PAGE. The ratio between FVIII single chain protein (SC) to heavy chain (HC, A1 and A2; 90 kDa)/light chain (LC, A3-C1-C3; 73 kDa) was calculated by optical densitometry using the TotalLab Quant software (Newcastle Upon Tyne, England). Carbohydrate analysis was carried out using recombinant N-glycosidase F (New England Biolabs, Ipswich, MA) or neuraminidase (QA-Bio, Palm Desert, CA) as reported before 14 . FVIII activity was determined by oneor two-stage activated partial thromboplastin time (aPTT) assays as previously described 9 .
Decay of activated FVIII activity
We determined the decay of activated forms of FVIII-BDD and FVIII-RH using a modified two-stage aPTT. Briefly, 20 nM purified FVIII-BDD or FVIII-RH was activated For personal use only. on October 22, 2017. by guest www.bloodjournal.org From in the presence of 40 nM α-thrombin (Haematologic Technologies, Essex Junction, VT).
The reaction was quenched by 60 nM hirudin (Sigma-Aldrich, St. Louis, MO) and serially diluted. Activity was assayed by aPTT at several time points thereafter, and quantitated based on known concentrations of BDD-FVIII (ReFacto, Pfizer, Cambridge, MA). Observed decay rates were calculated by fitting to a single exponential decay.
Recombinant AAV vectors production
AAV serotype 8 vectors were produced by a triple transfection protocol as previously described 4 . Three vector lots of each FVIII transgene were produced and quantified by silver staining in the same gel to optimize the determination of the amounts of physical particles delivered by each vector.
Animal models and vector injection
The Institutional Animal Care and Use Committee approved all animal experiments.
Adult HA mice on a C57Bl6/129Sv background or HA mice were crossed with CD4-knockout mice to obtain HA/CD4null mice. Transgenic HA mice with platelet-specific expression of human BDD-FVIII-BDD were previously reported 15 . Animals received AAV vector by tail vein injection diluted in saline solution.
FVIII antigen and activity levels in mice
Levels of circulating FVIII antigen were determined from citrated plasma using matchedpair antibodies to FVIII (Affinity Biologicals, Ontario, Canada) using serial dilutions of BDD-FVIII (ReFacto, Pfizer, New York, NY). Coagulant activity of FVIII-BDD and FVIII- 
Antibodies to FVIII and AAV capsid
Detection of mouse FVIII-specific IgG antibodies to human FVIII was performed using full-length FVIII (Recombinate, Baxter, Deerfield, IL) at a concentration of 20 U/mL to capture the total IgG antibodies in mouse serum using enzyme-linked immunosorbent assay (ELISA). Murine IgG (Sigma-Aldrich) was used as a standard by coating serial dilutions, and IgG was detected with 1:2000 anti-murine IgG (H+L) conjugated to horseradish peroxidase (Millipore, Billerica, MA). Inhibitory antibody titers to FVIII were detected by Bethesda assays using pooled normal human plasma to determine the residual activity of the protein in human FVIII deficient plasma as described previously 4 .
Detection of antibodies to AAV capsid was carried out as reported with minor modifications 16 .
Tail clip assay
Mice were pre-warmed at 37°C, the tail was transected at 3 mm diameter and blood collected for 10 minutes. Total blood loss (μl) was determined by converting the hemoglobin content using standard curves established with known amounts of mouse whole blood 17 .
Carotid artery injury model
Ferric chloride (FeCl 3 )-induced injury was carried out as described 17, 18 . We used two concentrations of FeCl 3 (7.5% or 15%) for 2 minutes at the adventitial surface of the For personal use only. on October 22, 2017. by guest www.bloodjournal.org From vessel to induce injury and the vessel was then washed with saline. In the case of injury after tail vein infusion of FVIII protein, the time from infusion to injury was 15 minutes.
Cremaster arteriole injury model
Laser-induced arteriole of the cremaster muscle was performed as reported 17, 18 . We determined platelet and fibrin accumulation at the injury site following injection of 
Copy Number and mRNA analysis
Livers from mice receiving AAV were collected for genomic DNA and RNA isolation. 
Statistical analysis
All data are presented as mean ± SEM. Comparison of data among experimental groups was analyzed by unpaired Student t test or analysis of variance (ANOVA).
Results
Biochemical characterization of FVIII R1645H (FVIII-RH) variant
We generated a human FVIII derivative with the canine (H1645) sequence recognized by PACE/furin (Fig 1A,B) . We found that FVIII-RH yields 0.27 mg/L, which is 2.5-higher than 0.10 mg/L for the FVIII-BDD. The latter is within the typical yields we reported for the FVIII-BDD (0.16 mg/L) using an identical expression system in BHK cells 9 .
Recombinant human FVIII-BDD and FVIII-RH proteins migrate in a similar fashion on SDS-PAGE under reducing conditions (Fig 1A) , and the percentage of single-chain form increased by 2.5-fold for the FVIII-RH compared to FVIII-BDD (52% vs. 20% singlechain form, respectively) by densitometric analysis. The slower migration pattern of the heavy chain was noted for the FVIII-RH compared to FVIII-BDD ( Figure 1A ). We sought to determine whether carbohydrate post-translational modifications differ between FVIII forms. Removal of N-linked glycans or sialic acid residues resulted in similar migration of the heavy chain from both FVIII forms (data not shown). Thus, it remains possible that the O-linked glycan pattern may be different between FVIII-RH and FVIII-BDD. Both FVIII variants were correctly processed by thrombin to yield the expected heterotrimer forms ( Fig 1A) . We next monitored the decay of FVIII variants upon activation with thrombin using clotting assays. The data showed that the half-life of activated FVIII-RH findings reflect a slow dissociation of the A2 domain from the A1/A3-C1-C2 heterodimer from the FVIII-RH compared to FVIII-BDD. Moreover, the superior activity of FVIII-RH was also determined by a two-stage aPTT assay (Fig 1D) . In these experiments, a dilution of FVIII-containing plasma samples is preincubated with thrombin for 30 sec before the measurement of FVIII activity, using a clotting assay 19 . The data showed a rapid onset of activated FVIII-RH generation compared with FVIII-BDD (Fig. 1D) ; however, the increased activity of FVIII cannot be detected using the one-stage aPTT assay.
FVIII-RH exhibits enhanced pro-hemostatic effects in murine models of HA upon vascular injury
To evaluate the efficacy of FVIII-RH compared to FVIII-BDD in vivo, we used a series of (Fig 2, left panels) . The data represents a total of 10-15 injuries (n= 3 mice/FVIII variant) for the low dose cohort, and 25 injuries (n=5 mice/FVIII variant) for the high dose cohort. Thus, FVIII-RH exhibits enhanced hemostatic effects in the microcirculation.
We next tested the procoagulant effects of FVIII variants with a FeCl 3 -induced injury in the carotid artery model. In the untreated HA mice no clot is formed for the duration of the experiment (30 min) using a FeCl 3 concentration of 7.5%. Injection of the proteins in HA mice showed that the time to full occlusion for the FVIII-RH (n=5 mice) is shortened compared to FVIII-BDD (n=4 mice) (p<0.018, Fig 3A) . In all protein injected animals the thrombi formed were stable throughout the duration of the experiment. Lastly, we monitored blood loss following tail clip (at 3 mm diameter) in HA mice (n=3 per group/dose) over a 10 min period after injection of protein. The data presented in Fig 3B demonstrate that FVIII-RH resulted in a reduction of blood loss compared to FVIII-BDD (p=0.023) at low doses (20 μg/kg), but not at higher doses (Fig 3B) . These findings were not due to differences in the protein pharmacokinetics since there were no distinctions in the recovery (15 min time point) and calculated half-life of both FVIII-RH and FVIII-BDD (data not shown). Taken together, these findings suggest that FVIII-RHinduced hemostasis in macrocirculation-injury models is superior to FVIII-BDD protein notably at the lowest dose tested.
FVIII-RH is associated with increased circulating expression levels in a dose-dependent manner following AAV liver gene therapy
Due to the promising data obtained with FVIII-RH protein, we sought to determine whether these findings could be translated into a model of continuous endogenous expression of these variants. Transgene expression was under the control of a hepatocyte-specific promoter (Fig. 4) . HA/CD4 deficient mice received AAV-FVIII-BDD or AAV-FVIII-RH at doses ranging from 8x10 12 vector genomes (vg)/kg to 4x10 13 vg/kg.
In all three cohorts, the expression levels of FVIII-RH were ~2-fold higher than FVIII-BDD ( Fig 5A) . FVIII clotting activity determined by chromogenic assay showed a good correlation with FVIII antigen levels ( Fig 5B) .
To further determine the underlying mechanism of the superior expression levels of FVIII-RH, we determined the levels of vector genomes by Q-PCR and FVIII RNA by RT-PCR in both groups of mice at week 14-17 post-vector injection. Vector DNA content in the liver showed no statistical difference between gene copy numbers for the FVIII-RH and FVIII-BDD (Fig 5C) , as expected. There was variation in the RNA levels between groups of mice expressing FVIII-RH or FVIII-BDD but these differences did not reach statistical significance. The correlation between FVIII expression levels with FVIII-RNA showed that increased circulating FVIII-RH levels is unlikely due to RNA content ( Fig   5D) . Together these data suggest that the high levels of FVIII-RH may occur, at least in part, at the posttranscriptional level and are most likely secreted more efficiently than the FVIII-BDD (Table 1) .
For
FVIII-RH is more effective than FVIII-BDD in induce hemostasis in vivo upon vascular injury models
To test whether the FVIII-RH variant could correct hemostasis at comparable levels to the FVIII-BDD, we grouped AAV injected mice accordingly by FVIII expression plateau levels. We empirically normalized the FVIII levels in two groups (Fig 6) by antigen levels since there is a direct correlation with FVIII activity. All FVIII-expressing mice exhibited reduced blood loss compared to untreated HA mice (p < 0.001 for all groups) (Fig 6) .
There was a direct correlation between circulating FVIII levels and the volume of blood loss. At intermediate levels (70-95 ng/ml), the blood loss in the FVIII-RH was reduced compared to FVIII-BDD (p<0.04). However, blood loss was similar between both groups expressing FVIII at levels higher than 100 ng/ml, and these values are comparable with those of hemostatically normal mice (90-100 μl).
In addition, we sought to define the procoagulant effect of FVIII variants in the carotid artery model using 7.5% or 15% FeCl 3 challenges. Because there is an inverse correlation between the time for occlusion and FVIII levels, the time of occlusion was not an endpoint in this model since this reflects the FVIII expression levels. Here we focused on the assessment of clot stability over a period of 30 min as the endpoint. In 3 out of 7 mice expressing FVIII-BDD the clot formed was transient, whereas in all FVIII-RH animals exhibited stable clots (Table 2) . We next used the 7.5% FeCl 3 model to refine the differences between both forms of FVIII. The data showed transient clots formed in 3 of 10 FVIII-BDD mice, and 1 of 5 for the FVIII-RH mice, expressing less than 100 ng/ml. Moreover, since the endogenous levels following AAV delivery were
high, there were no differences in the fibrin deposition and platelet accumulation in the laser-induced injury model (data not shown). Again, consistent with the findings of the blood loss, there was no difference in clot stability in mice expressing more than 100 ng/ml of FVIII forms. Nevertheless, these data suggest that FVIII-RH induced the formation of clots with improved stability compared to FVIII-BDD.
No increased immunogenicity by FVIII-RH variant in mice tolerant to FVIII-BDD
The risk of immune response to variant forms of FVIII is a major safety concern; thus, we tested whether FVIII-RH could be associated with a high risk of antibody formation 15 .
We used HA transgenic mice for platelet-specific expression of human FVIII-BDD with no detectable circulating FVIII. Female mice received AAV vectors encoding FVIII-RH (n=7) or FVIII-BDD (n=5) at doses of 8x10 12 vg/kg. Circulating FVIII levels ranged from 10-33% for the FVIII-BDD, and 18-48% for the FVIII-RH (Fig 7A) , and were somewhat lower than the male HA groups. As previous reported, female mice expressed lower levels of the transgene by liver-directed gene transfer by AAV vectors in a serotypeindependent manner 20 . No antibody formation to human FVIII was detected by Bethesda assay (Fig 7B) or by anti-human FVIII-specific IgG during a period of 6-12 weeks post-vector injection (Fig 7C) . In contrast, naïve HA mice developed antibodies following FVIII-BDD protein injection (Fig 7C) or AAV-FVIII-BDD (unpublished observations) as also reported by others 21 . In order to confirm that the immune tolerance to FVIII forms was transgene specific, we measured anti-AAV8-specific capsid IgG levels. All animals developed a robust anti-capsid immune response (Fig 7D) 
Discussion
Recent developments in bioengineering of coagulation factors for the treatment of hemophilia resulted in a series of novel proteins with advantageous biological functions.
Molecules with prolonged half-life or high specific activity, as well as recombinant expression systems that optimize the rates of protein production are in preclinical development or in early-phase clinical trials 22, 23 . The ultimate goal is to obtain a therapeutic protein with enhanced biological activity without increased immunogenicity.
Our early studies on the biochemical and in vivo characterization of canine-BDD-FVIII showed the attractive features of this protein, specifically its stability and/or enhanced procoagulant activity. We sought to determine whether these could be amenable to the human FVIII-BDD-F 9 . The canine FVIII B domain has a unique putative recognition sequence for PACE/furin 11 that differs from all other species tested, and thus offers the opportunity to modify the human sequence, FVIII-RH, to determine if this single amino acid change could affect the biology of the human derivative. The introduction of H1645 increased the secretion of single-chain protein by 2.5-fold compared to FVIII-BDD (20%), which is now closer to the amount of the canine single-chain form (75%).
Moreover, the A2 dissociation from the A1/A3-C1-C2 heterodimer was delayed by ~3-fold, and exhibits higher protein activity in a series of coagulation studies in vitro. The To test the impact of the FVIII-RH protein in inducing hemostasis upon vascular injuries, we challenged HA mice in the macrocirculation (tail vessels and carotid artery). In both models, FVIII-RH exhibits a more effective procoagulant effect than FVIII-BDD.
Moreover, monitoring of real time thrombus formation in the microcirculation showed that FVIII-RH induces a higher content of fibrin deposition, and faster platelet accumulation at the injury site compared to the FVIII-BDD as better evidenced in the low dose cohorts. Taken together, these data led us to speculate that the superior performance of FVIII-RH is likely the result of higher protein stability (delayed A2 domain dissociation) and consequent robust thrombus formation.
Translational studies on promising gene-based strategies for hemophilia are critical to define the efficacy of the transgene product as well as its immunogenicity 1, 25 . Moreover, in two early phase clinical trials for hemophilia B using AAV for liver-restricted expression, there was a direct correlation between the risk of unwanted immune cellular responses to the transduced cells and the vector dose administered 1, 2, 26 . Thus, there . Here we sought to test liver-based gene therapy using AAV-FVIII-RH as a strategy to enhance endogenous FVIII expression levels and biological activity. Notably, circulating levels of FVIII-RH were higher than in HA mice injected with AAV-FVIII-BDD at all three-dose cohorts. These findings were unexpected since we anticipated that the benefits of this variant would be related mostly to the procoagulant effects. However, the rates of increased expression levels in vivo are consistent, to a certain extent, with data obtained in vitro with the higher yields of recombinant FVIII-RH expression compared to the FVIII-BDD.
Analysis of the FVIII transcripts showed comparable RNA levels, although with some variability, within the same dose cohort for both FVIII variants. Thus, it is possible that increased levels of circulating FVIII-RH are unlikely solely due to RNA content. We speculate that, at least in part, FVIII-RH is secreted more efficiently than FVIII-BDD, which supports the finding of high levels of expression of the transgene product. Similar 
formed at the carotid artery. Because of the relatively high levels of FVIIII-RH and FVIII-BDD, there were no differences in fibrin deposition and platelet content in the thrombus formation in the microcirculation. Overall, these findings from the carotid artery and the cremaster arteriole are consistent with data observed in mice expressing FVIII-BDD ectopically in platelets that was improved by expression of canine FVIII 15 , and in the recent data using FVIII-RH in platelets (M.P., personal communication, October 2012).
To address the safety concern of the immunogenicity of FVIII-RH, we used HA mice tolerant to human BDD-FVIII due to transgenic expression of FVIII in platelets but not detectable in the plasma. Following vector injection, circulating levels of FVIII-RH were 2-fold higher than FVIII-BDD, as observed in HA/CD4 deficient mice. No antibody to human FVIII was detected in these animals. Thus, FVIII-RH does not exhibit higher immunogenicity than FVIII-BDD. These transgenic mice mounted normal humoral responses to the AAV capsid, which suggested that the tolerance to FVIII forms were transgene specific and not a general immunosuppressive response.
Cumulative data showed that the most common epitopes associated with inhibitor formation in HA patients on protein therapy are located at the A2 and C2 domains and these findings are also obtained in HA mice injected with human FVIII protein 31, 32 . To date, there is no conclusive evidence on distinct rates of inhibitor formation comparing recombinant BDD or full-length FVIII 8 . Moreover, the B domain sequence is the most polymorphic of the all FVIII domains 10, 33 . Together these findings suggest that minimal modifications in B-domain sequence, as reported here, may not increase FVIII 
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